Condition
Mild Hypertension
Total Trials
5
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
25%
1 of 4 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 1 (2)
P 2 (2)
Trial Status
Completed4
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06905327Phase 1CompletedPrimary
A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects
NCT03714776Phase 2CompletedPrimary
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure
NCT04908917Not ApplicableUnknownPrimary
Reducing Air Pollution to Lower Blood Pressure
NCT01331486Phase 1Completed
Nitric Oxide Mediated Vasodilatory Response to Hawthorn Standardized Extract
NCT00374855Phase 2CompletedPrimary
A Study in People With Mild Hypertension
Showing all 5 trials